Certain psychedelics, including psilocybin, may be useful for treating depression. Could they be a game-changing breakthrough for psychiatry?
Clinical depression causes misery for hundreds of millions of people worldwide. Around one in five patients fail to respond to any therapy and even among those who do regain, relapse rates are high and get progressively worse with each successive episode.
The most widely used class of antidepressants, the selective serotonin reuptake inhibitors( SSRIs ), can lift some people out of severe depression and help them remain well, but they dont work for everyone, and among the many side-effects are nervousnes, weight gain and sex dysfunction. Since the SSRIs became available in the 1980 s no new class of drugs has emerged, so the news that there may already be a more effective type of antidepressant in existence that is safe and well tolerated is tantalising. The catch is that to possess or furnish these chemicals runs the risk of an unlimited fine or prison sentence.
What scientific proof would convince governments to reclassify psychedelics so they could be used for therapeutic purposes? For now, there is a lack of results from large, randomised-controlled clinical trials, but small studies are providing a strong theoretical basis for the claim that these narcotics qualify as a new class of antidepressant. Whether thats enough to get them reclassified is another question.
In the 1950 s and 60 s, before the ban came into force, psychiatrists were beginning to explore their usefulness for treating nervousnes, depression and craving. Only recently has this research re-started, with pilot analyzes hinting that the psychedelics psilocybin( the active ingredient of magic mushroom) and ayahuasca may have profound antidepressant impacts. In the most recent, published in The Lancet Psychiatry on Tuesday[ pdf ], 12 patients with treatment-resistant depression “ve been given” two dosages of psilocybin one week apart. A week after the therapy, eight patients were completely free of depressive symptoms. Five was currently in remission three months later. The narcotic was well tolerated and there were no unexpected adverse events.
In February, a similar examine was published in which 17 patients with recurrent depression took a single dose of the hallucinogenic brew ayahuasca. Immediately before, and at weekly intervals up to three weeks later, they filled out written questionnaire to assess the severity of their depression. During the hallucinogenic experience their brains were scanned employing photon emission tomography( PET ), which revealed increased blood flow in regions involved in the regulation of mood and feelings. There were significant improvements in their mean depression ratings that began 80 minutes after the dose and lasted at least three weeks. Vomiting was the only adverse effect, experienced by around half of the patients shortly after taking the drug.
The common biochemical factor underlying the effects on the brain of psychedelics is that they bind to the 5-HT2A serotonin receptor. Molecules that activate this receptor are known to stimulate production of a nerve growth factor called BDNF( brain-derived neurotrophic factor) and enhance the efficiency of signalling between nerve cells. The acute effects of LSD on brain activity were graphically demonstrated in an fMRI study published last month which showed how networks of regions that usually operate independently became more functionally interconnected they started talking to each other while connectivity within another network associated with mind-wandering and the sense of ego, called the default mode network, broke down.
A similar examine of the brains of people who had taken psilocybin, published in 2012, also uncovered interruption in communication between key nodes of the default mode network. This may be key to the antidepressant potential of psychedelics, because this network is overactive in people who are prone to depression and is thought to be responsible for the excessive self-referential thought and rumination that characterises the condition.